DK3303384T3 - Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf - Google Patents

Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf Download PDF

Info

Publication number: DK3303384T3
Authority: DK; Denmark
Prior art keywords: binding molecules; neutralizing anti; influenza binding; influenza; neutralizing
Prior art date: 2015-06-01

Application number

DK16728534.5T

Other languages

English (en)

Inventor

Nicole Kallewaard-Lelay

Qing Zhu

Godfrey Jonah Rainey

Cuihua Gao

Srinath Kasturirangan

Changshou Gao

Original Assignee

Medimmune Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-01

Filing date

2016-05-31

Publication date

2021-10-18

2016-05-31 Application filed by Medimmune Llc filed Critical Medimmune Llc

2021-10-18 Application granted granted Critical

2021-10-18 Publication of DK3303384T3 publication Critical patent/DK3303384T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK16728534.5T 2015-06-01 2016-05-31 Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf DK3303384T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562169272P	2015-06-01	2015-06-01
PCT/US2016/035026 WO2016196470A1 (en)	2015-06-01	2016-05-31	Neutralizing anti-influenza binding molecules and uses thereof

Publications (1)

Publication Number	Publication Date
DK3303384T3 true DK3303384T3 (da)	2021-10-18

Family

ID=56118059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16728534.5T DK3303384T3 (da)	2015-06-01	2016-05-31	Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf

Country Status (22)

Country	Link
US (4)	US10442854B2 (da)
EP (2)	EP3303384B1 (da)
JP (3)	JP6867306B2 (da)
CN (2)	CN107667114B (da)
AU (2)	AU2016271323B2 (da)
BR (1)	BR112017025496A2 (da)
CA (1)	CA2987816C (da)
CY (1)	CY1125793T1 (da)
DK (1)	DK3303384T3 (da)
ES (1)	ES2894777T3 (da)
HK (2)	HK1250725A1 (da)
HR (1)	HRP20211510T1 (da)
HU (1)	HUE056407T2 (da)
LT (1)	LT3303384T (da)
MX (2)	MX2017015189A (da)
PL (1)	PL3303384T3 (da)
PT (1)	PT3303384T (da)
RS (1)	RS62446B1 (da)
RU (1)	RU2721706C2 (da)
SI (1)	SI3303384T1 (da)
SM (1)	SMT202100591T1 (da)
WO (1)	WO2016196470A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3733244A1 (en)	2013-10-02	2020-11-04	Medlmmune, LLC	Neutralizing anti-influenza a antibodies and uses thereof
RU2739952C2 (ru)	2014-07-15	2020-12-30	МЕДИММЬЮН, ЭлЭлСи	Нейтрализующие антитела к вирусу гриппа b и пути их применения
HRP20211510T1 (hr)	2015-06-01	2021-12-24	Medimmune, Llc	Neutralizirajuće vezujuće molekule protiv influence i njihova uporaba
IL260413B2 (en)	2016-01-13	2024-01-01	Medimmune Llc	A method for treating type A influenza
IL275884B2 (en)	2018-01-26	2024-11-01	Regeneron Pharma	Human antibodies to influenza hemagglutinin
WO2021086899A1 (en)	2019-10-28	2021-05-06	Regeneron Pharmaceuticals, Inc.	Anti-hemagglutinin antibodies and methods of use thereof
CN113121680B (zh) *	2021-04-12	2022-03-29	华南农业大学	一种抗h5亚型禽流感纳米抗体蛋白及其编码基因与应用
WO2023196658A2 (en) *	2022-04-08	2023-10-12	Cz Biohub Sf, Llc	Antibody compositions and optimization methods
CN116874606B (zh) *	2023-09-08	2023-11-24	益科思特(北京)医药科技发展有限公司	一种靶向trop2和cd3的双特异性抗体及其制备方法与应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154600B (nl)	1971-02-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3766162A (en)	1971-08-24	1973-10-16	Hoffmann La Roche	Barbituric acid antigens and antibodies specific therefor
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4233402A (en)	1978-04-05	1980-11-11	Syva Company	Reagents and method employing channeling
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en)	1982-06-24	1989-11-23	Japan Chem Res	Long-acting composition
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5981216A (en)	1985-04-01	1999-11-09	Alusuisse Holdings A.G.	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
PT859841E (pt)	1995-08-18	2002-11-29	Morphosys Ag	Bibliotecas de proteinas/ (poli) peptidos
SE9504046D0 (sv)	1995-11-14	1995-11-14	Pharmacia Ab	Method of determining affinity and kinetic properties
EP0901630B1 (en)	1996-05-23	2003-08-20	Inverness Medical Switzerland GmbH	Improvements in or relating to specific binding assays
AU8063798A (en)	1997-06-19	1999-01-04	Regents Of The University Of California, The	Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
WO2000029584A1 (en)	1998-11-18	2000-05-25	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en)	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
CA2365575A1 (en)	1999-03-31	2000-10-12	Otsuka Pharmaceutical Co., Ltd.	Influenza virus hemagglutinin-binding peptides
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
EP1264885A4 (en)	2000-02-22	2007-02-21	Med & Biological Lab Co Ltd	ANTIBODY LIBRARY
EP2119793A1 (en)	2000-06-28	2009-11-18	Glycofi, Inc.	Methods for producing modified glycoproteins
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
JP2005530845A (ja)	2002-06-21	2005-10-13	アイデックファーマシューティカルズコーポレイション	抗体を濃縮するための緩衝化処方物およびその使用方法
AU2003251809A1 (en)	2002-07-11	2004-02-02	The General Hospital Corporation	Polynucleotide and polypeptide fat metabolism regulators and uses thereof
JP4595810B2 (ja)	2003-07-23	2010-12-08	富士レビオ株式会社	抗インフルエンザａ型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具
KR101280094B1 (ko)	2003-08-11	2013-06-28	사이단호진한다이비세이부쯔뵤우겐큐우카이	점막 면역을 유도할 수 있는 보강제를 함유한 신규한 백신
ATE443084T1 (de)	2004-07-10	2009-10-15	Fox Chase Cancer Ct	Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
WO2006124269A2 (en)	2005-05-16	2006-11-23	Amgen Fremont Inc.	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
PL2532679T3 (pl)	2005-10-21	2017-09-29	Novartis Ag	Ludzkie przeciwciała przeciwko IL13 i zastosowania terapeutyczne
BRPI0707290A2 (pt)	2006-01-17	2011-08-16	Biolex Therapeutics Inc	composições e métodos para humanização e otimização de n-glicanas em plantas
US8343489B2 (en)	2006-03-21	2013-01-01	Weaver David T	Methods for humanizing antibodies and humanized antibodies made thereby
WO2007117577A2 (en)	2006-04-07	2007-10-18	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human il-18 receptor
WO2007134327A2 (en)	2006-05-15	2007-11-22	Sea Lane Biotechnologies, Llc.	Neutralizing antibodies to influenza viruses
KR101485197B1 (ko)	2006-09-07	2015-01-23	크루셀 홀란드 비.브이.	인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
LT2769992T (lt)	2006-10-02	2021-04-12	Regeneron Pharmaceuticals, Inc.	Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
CA2668800A1 (en)	2006-11-08	2008-06-05	Macrogenics West, Inc.	Tes7 and antibodies that bind thereto
RU2448979C2 (ru)	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
GB0700133D0 (en)	2007-01-04	2007-02-14	Humabs Llc	Human cytomegalovirus neutralising antibodies and use thereof
JP5346820B2 (ja)	2007-03-13	2013-11-20	エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー	Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
EP1995309A1 (en)	2007-05-21	2008-11-26	Vivalis	Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it)	2008-03-17	2009-09-18	Pomona Biotechnologies Llc	Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it)	2008-05-27	2009-11-28	Pomona Biotechnologies Llc	Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8871207B2 (en)	2008-07-25	2014-10-28	Humabs, LLC	Neutralizing anti-influenza A virus antibodies and uses thereof
KR20110049802A (ko)	2008-07-25	2011-05-12	인스티튜트 포 리서치 인 바이오메드슨	중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
EP3301116A1 (en)	2008-08-25	2018-04-04	Dana Farber Cancer Institute, Inc.	Conserved influenza hemagglutinin epitope and antibodies thereto
JP5882058B2 (ja)	2008-11-07	2016-03-09	ファブラスエルエルシー	組合せ抗体ライブラリー及びその使用
US9512182B2 (en)	2010-12-13	2016-12-06	University Of Utah Research Foundation	Vaccine antigens that direct immunity to conserved epitopes
KR101941724B1 (ko)	2011-07-14	2019-01-23	얀센 백신스 앤드 프리벤션 비.브이.	계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자
DK2734545T3 (da)	2011-07-18	2019-04-15	Inst Res Biomedicine	Neutraliserende anti-influenza a-virusantistoffer og anvendelser deraf
SG11201400743VA (en)	2011-09-20	2014-04-28	Sinai School Medicine	Influenza virus vaccines and uses thereof
CA2849822C (en)	2011-09-23	2021-05-11	Gary J. Nabel, M.D.	Novel influenza hemagglutinin protein-based vaccines
BR112014013640A8 (pt) *	2011-12-05	2021-03-16	Trellis Bioscience Llc	anticorpos úteis em imunização passiva para influenza
CA2865594C (en) *	2012-03-08	2021-07-27	Crucell Holland B.V.	Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
CN104968367B (zh)	2012-11-13	2018-04-13	弗·哈夫曼-拉罗切有限公司	抗血凝素抗体和使用方法
KR20140118682A (ko)	2013-03-29	2014-10-08	(주)셀트리온	2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) *	2013-08-05	2014-12-27	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства"	Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
EP3733244A1 (en) *	2013-10-02	2020-11-04	Medlmmune, LLC	Neutralizing anti-influenza a antibodies and uses thereof
RU2739952C2 (ru)	2014-07-15	2020-12-30	МЕДИММЬЮН, ЭлЭлСи	Нейтрализующие антитела к вирусу гриппа b и пути их применения
HRP20211510T1 (hr)	2015-06-01	2021-12-24	Medimmune, Llc	Neutralizirajuće vezujuće molekule protiv influence i njihova uporaba
IL260413B2 (en)	2016-01-13	2024-01-01	Medimmune Llc	A method for treating type A influenza
WO2017147248A1 (en)	2016-02-24	2017-08-31	Visterra, Inc.	Formulations of antibody molecules to influenza virus

2016
- 2016-05-31 HR HRP20211510TT patent/HRP20211510T1/hr unknown
- 2016-05-31 SI SI201631344T patent/SI3303384T1/sl unknown
- 2016-05-31 PT PT16728534T patent/PT3303384T/pt unknown
- 2016-05-31 EP EP16728534.5A patent/EP3303384B1/en active Active
- 2016-05-31 PL PL16728534T patent/PL3303384T3/pl unknown
- 2016-05-31 US US15/577,799 patent/US10442854B2/en active Active
- 2016-05-31 CN CN201680030393.8A patent/CN107667114B/zh active Active
- 2016-05-31 JP JP2017561892A patent/JP6867306B2/ja active Active
- 2016-05-31 MX MX2017015189A patent/MX2017015189A/es unknown
- 2016-05-31 ES ES16728534T patent/ES2894777T3/es active Active
- 2016-05-31 RU RU2017145094A patent/RU2721706C2/ru active
- 2016-05-31 CA CA2987816A patent/CA2987816C/en active Active
- 2016-05-31 SM SM20210591T patent/SMT202100591T1/it unknown
- 2016-05-31 CN CN202110755761.8A patent/CN113480640B/zh active Active
- 2016-05-31 RS RS20211271A patent/RS62446B1/sr unknown
- 2016-05-31 BR BR112017025496-4A patent/BR112017025496A2/pt active Search and Examination
- 2016-05-31 WO PCT/US2016/035026 patent/WO2016196470A1/en active Application Filing
- 2016-05-31 LT LTEPPCT/US2016/035026T patent/LT3303384T/lt unknown
- 2016-05-31 DK DK16728534.5T patent/DK3303384T3/da active
- 2016-05-31 AU AU2016271323A patent/AU2016271323B2/en active Active
- 2016-05-31 HU HUE16728534A patent/HUE056407T2/hu unknown
- 2016-05-31 EP EP21186517.5A patent/EP3960761A1/en active Pending
2017
- 2017-11-27 MX MX2022001220A patent/MX2022001220A/es unknown
2018
- 2018-08-03 HK HK18110009.8A patent/HK1250725A1/zh unknown
- 2018-09-28 HK HK18112479.5A patent/HK1253092A1/zh unknown
2019
- 2019-09-04 US US16/560,040 patent/US10882897B2/en active Active
2020
- 2020-12-01 US US17/108,608 patent/US11524993B2/en active Active
2021
- 2021-04-08 JP JP2021065590A patent/JP2021112193A/ja active Pending
- 2021-10-21 CY CY20211100923T patent/CY1125793T1/el unknown
2022
- 2022-11-11 US US18/054,757 patent/US11926657B2/en active Active
- 2022-11-18 AU AU2022271473A patent/AU2022271473A1/en active Pending
2023
- 2023-03-22 JP JP2023045036A patent/JP2023078352A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US11926657B2 (en)	2024-03-12
AU2016271323A1 (en)	2018-01-18
US20180155413A1 (en)	2018-06-07
US20210079069A1 (en)	2021-03-18
LT3303384T (lt)	2021-10-11
EP3303384B1 (en)	2021-08-25
MX2022001220A (es)	2022-03-02
MX2017015189A (es)	2018-04-13
CN113480640B (zh)	2024-07-30
CN113480640A (zh)	2021-10-08
CA2987816A1 (en)	2016-12-08
WO2016196470A1 (en)	2016-12-08
CN107667114B (zh)	2021-07-02
AU2022271473A1 (en)	2022-12-22
SMT202100591T1 (it)	2021-11-12
RS62446B1 (sr)	2021-11-30
CY1125793T1 (el)	2024-02-16
EP3960761A1 (en)	2022-03-02
RU2017145094A3 (da)	2019-11-06
JP2021112193A (ja)	2021-08-05
RU2017145094A (ru)	2019-07-09
PL3303384T3 (pl)	2022-01-03
PT3303384T (pt)	2021-10-14
SI3303384T1 (sl)	2021-11-30
CN107667114A (zh)	2018-02-06
HUE056407T2 (hu)	2022-02-28
US20230112916A1 (en)	2023-04-13
US10882897B2 (en)	2021-01-05
BR112017025496A2 (pt)	2018-08-07
US11524993B2 (en)	2022-12-13
HK1250725A1 (zh)	2019-01-11
ES2894777T3 (es)	2022-02-15
HK1253092A1 (zh)	2019-06-06
CA2987816C (en)	2024-02-20
EP3303384A1 (en)	2018-04-11
HRP20211510T1 (hr)	2021-12-24
US10442854B2 (en)	2019-10-15
RU2721706C2 (ru)	2020-05-21
JP6867306B2 (ja)	2021-04-28
US20200109187A1 (en)	2020-04-09
AU2016271323B2 (en)	2022-08-25
JP2023078352A (ja)	2023-06-06
JP2018518475A (ja)	2018-07-12

Publication	Publication Date	Title
IL256416B (en)	2021-12-01	Multispecific antigen-binding molecules and uses thereof
IL261942A (en)	2018-10-31	Bcma binding molecules and methods of use thereof
DK3265575T3 (da)	2021-05-31	Cd20-bindende molekyler og anvendelser deraf
HK1243925A1 (zh)	2018-07-27	針對流感血球凝集素的結合分子及其用途
LT3456346T (lt)	2021-09-27	Pd-1 ir lag-3 surišančios molekulės ir jų panaudojimo būdai
DK3380522T5 (da)	2024-09-30	Antistofmolekyler til april og anvendelser deraf
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
DK3303379T3 (da)	2021-12-06	Tigit-bindende midler og anvendelser deraf
DK3116909T3 (da)	2020-01-20	Antistofmolekyler til lag-3 og anvendelser deraf
HUE054339T2 (hu)	2021-08-30	CD73-ra specifikus kötõmolekulák és alkalmazásaik
DK3099172T3 (da)	2021-11-22	Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3155024T3 (da)	2020-11-23	Opholdsstrukturer og relaterede fremgangsmåder
DK3303384T3 (da)	2021-10-18	Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
DK3218358T3 (da)	2021-08-30	Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3105250T3 (da)	2020-09-28	Multispecifikke iga-bindingsmolekyler
DK3209773T3 (da)	2020-06-15	Prolintolerante tripeptidylpeptidaser og anvendelser deraf
HK1248721A1 (zh)	2018-10-19	抗體分子及其用途
LT3374398T (lt)	2020-09-10	Asct2 atžvilgiu specifinės surišančios molekulės ir jų panaudojimai
DK3242685T3 (da)	2022-07-25	Cxcr4-bindende molekyler
DK3417058T3 (da)	2021-11-15	Sortase-modificerede molekyler og anvendelser deraf
DK3128997T3 (da)	2020-08-24	Bindingmolekyler specifikke for il-21 og anvendelser deraf
EP3673066A4 (en)	2021-05-26	RNA MOLECULES
DK3280405T3 (da)	2021-09-06	Inhibitorer og anvendelser deraf
DK3365321T3 (da)	2024-01-15	Solabegron-zwitterion og anvendelser deraf
DK3337506T3 (da)	2021-09-06	Kombinationer og anvendelser deraf